TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Length for age Z-score (LAZ) at 18 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Drug-related AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Drug-related SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Benefits to future patients post-prostatectomy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antibody Persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity Booster Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient acceptance of diabetes self-management education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum Lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum non-cholesterol sterols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Genotype via single nucleotide polymorphism analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and rate of adverse events (AEs) within 30 minutes after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and rate of adverse events (AEs) within 7 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and rate of serious adverse events (SAEs) during 28 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in daily pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Performance evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of B17MP, formoterol and GB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum of Concentration (Cmax) of B17MP, FF and GB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrospective-Modified Overt Aggression Scale (R-MOAS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impulsive Aggression (IA) Measured by Clinical Global Impression - Severity Scale (CGI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impulsive Aggression (IA) Measured by Clinical Global Impression - Improvement Scale (CGI-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of nevirapine, stavudine and lamivudine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transition Readiness Assessment Questionnaire (TRAQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients on RoActemra/Actemra
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC(0-12),ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aCD19z T cell survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aCD19z T cell toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Hand dexterity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Higher sensitivity for detection using New High Resolution Contrast Enhanced MRI Imaging Sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher sensitivity for detection of peritoneal metastatic disease using Ultrasound Elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human plasma concentration of bioactives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival time after transformation to small cell lung cancer (SCLC)
Endpoint domain: Mortality/survival
Primary endpoint: Correlation of Skeletal Muscle Index and Fat Index with AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of Skeletal Muscle Index, Fat Index and AUC with Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Association of Age With Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modeled Hemoglobin Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tidal exhaled Nitrogen Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serostatus of hepatitis B viral markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Velocity orbicularis oris Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Velocity masseter Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Velocity Temporalis Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Velocity Buccinator Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Abdominal pain response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fasting Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: State Body Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in GI microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of registered medicines and supplements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall clinical response (PR and CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Change From Baseline in Total Sign Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature and Frequency of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change in The International Cooperative Ataxia Rating Scale (ICARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of colon irrigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Days to symptom resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Aspiration
Endpoint domain: Adverse events/effects
Primary endpoint: Hamstring Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of regurgitation at any cardiac valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regional Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of symptomatic and asymptomatic bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Office seated peripheral systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Diagnosis of the First Keratinocyte Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hazard Ratio for Surgically Treated KC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean number of adenomas per colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Milk Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BPI pain interference improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Narcolepsy prevalence
Endpoint domain: Mortality/survival
Primary endpoint: visual comfort index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: productivity (correct words edited per hour)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from baseline in ICIQ-Urinary Incontinence Short Form Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cytomegalovirus (CMV) specific immune reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Without Morbidity or Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Suicidal Ideation (adolescents)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Suicidal Ideation (adults)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of salivary cariogenic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CY-BOCS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Assault Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Change in the 6 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of chronic hepatitis C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 30 Day Smoking Quit Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Fugl-Meyer Motor Scale (FMMS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change From Baseline in Cue Nicotine Craving Rating Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Failure Free at 2 Years Following Study Entry
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients Experiencing a Grade 3 or Higher Adverse Event During Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Post-traumatic Stress Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of endothelial function markers (angiopoietin 1 and 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events and their intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in plasma amino acids concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in 1RM test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in protein metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline in macronutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in delayed onset muscle soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Average Change in Best-Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Receiving 3 Consecutive Monthly Vivitrol Injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants died within 30 days postoperatively
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants developed low cardiac output syndrome within the first 36 hours after initiation of study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Equivalence of injection administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving normalized Hb-levels or increased Hb of at least 1.5 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pre post difference of volume-corrected urine iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum anti-vaccine antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Death Rate
Endpoint domain: Mortality/survival
Primary endpoint: Estimation of thermal dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2 years recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of morphologic complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of healthy surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR corrected efficacy (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of incisions made during laparoscopic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: occurrence of clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Overall Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: AUC(0-24) of pazopanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax after repeat administration of pazopanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digital volume pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients who experience pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial Viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety parameters changes from baseline
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in number of terminal hair follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in number of anagen hair follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in number of telogen hair follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in number of catagen hair follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in number of vellus (vellus-like) miniaturized hair follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevention of iron-deficiency anemia in pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caregiver Reaction Assessment (CRA scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3 months outcome (composite outcome)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility and repeatability of OCT parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least 2*10^6 CD34+ Cells Per kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Health Survey 36 Short Form (SF36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Female Sexual Functioning Index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Target Lesion Primary Patency at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Lesion Primary Patency at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Lesion Primary Patency at 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Major Device, Procedure and Treatment Site-related Adverse Events Through 30 Days Post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking Abstinence at 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stent expansion index (SEI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major edge dissections and geographical mismatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete elimination of muscle cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Medically-attended adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic Intracerebral Hemorrhage (ICH)
Endpoint domain: Adverse events/effects
Primary endpoint: Major Systemic Hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Other Serious Adverse Event Related to Study Drug Administration, Including Death
Endpoint domain: Adverse events/effects
Primary endpoint: weight loss at least 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: waist reduction at least 4%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical activity at least 30 minutes per day (3h per week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global cognition-Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean number of confirmed UTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Graft rejection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of premature aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcomes measured by Knee Society Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline of Soft Tissue Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Minor Tissue Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute hemodynamic response judged by dP/dt max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of local and/or systemic infections
Endpoint domain: Adverse events/effects
Primary endpoint: coronary microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Driver airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Static airway compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dynamic airway compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End tidal CO2 pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tumor Apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Cognitive Abilities of Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Cognitive Abilities of Reasoning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Cognitive Abilities of Speed of Processing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3 Year Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and/or Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from baseline impact of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Presence of amblyopia / strabismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Number of enhanced lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET scan modification in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes